Incretin mimetics and enhancers for the treatment of type 2 diabetes mellitus.
Recently, new therapeutic strategies based on the incretin system have been developed
. The incretin hormones glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) are released from the gut in response to food intake and are responsible for the postprandial increase in insulin secretion. GLP-1 and GIP are rapidly degraded by